Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026

European Medicines Agency Version 1 original current

Imported from official source

Seven new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended seven medicines for approval at its November 2026 meeting.The committee…, CHMP statistics Key figures from the November 2026 CHMP meeting are represented in the graphic below. © European Medicines Agency , CHMP statistics:…, Positive recommendations on new medicines, Aumseqa International non-proprietary name (INN) aumolertinib Marketing authorisation applicant SFL Pharmaceuticals Deutschland GmbH Therapeutic indication…, Baxfendy INN baxdrostat Marketing authorisation applicant AstraZeneca AB Therapeutic indication Treatment of hypertension in adults More information…, Zybrivo INN sintilimab  Marketing authorisation applicant Fortvita Biologics (Ireland) Limited Therapeutic indication Treatment of non-squamous non…, Positive recommendations on new biosimilar medicines, Garzulys INN insulin aspart Marketing authorisation applicant Sciencepharma Sp. z o.o. Therapeutic indication Treatment of diabetes mellitus from 1 year of…, Donrafylix INN insulin aspart Marketing authorisation applicant Kuraci Therapeutic indication Treatment of diabetes mellitus from 1 year of age...

This version

Version
1 of 1
Recorded
November 13, 2026 11:01
Change
Initial
Content hash
b54fbe69e97605d824d77b1086d78612
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.